tiprankstipranks
Aptinyx Inc (APTX)
NASDAQ:APTX

Aptinyx Stock Analysis & Ratings

APTX Stock Chart & Stats

Day’s Range$0.63 - $0.7531
52-Week Range$0.57 - $4.73
Previous Close$0.7
Volume347.08K
Average Volume (3M)349.78K
Market Cap$42.83M
P/E Ratio-0.6
Beta1.46
Next EarningsAug 17, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-1.11


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

APTX FAQ

What was Aptinyx’s price range in the past 12 months?
Aptinyx lowest stock price was $0.57 and its highest was $4.73 in the past 12 months.
    What is Aptinyx’s market cap?
    Aptinyx’s market cap is $42.83M.
      What is Aptinyx’s price target?
      The average price target for Aptinyx is $4.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $2.00. The average price target represents 611.46% Increase from the current price of $0.633.
        What do analysts say about Aptinyx?
        Aptinyx’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is Aptinyx’s upcoming earnings report date?
          Aptinyx’s upcoming earnings report date is Aug 17, 2022 which is in 91 days.
            How were Aptinyx’s earnings last quarter?
            Aptinyx released its earnings results on May 12, 2022. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.304 by $0.014.
              Is Aptinyx overvalued?
              According to Wall Street analysts Aptinyx’s price is currently Undervalued.
                Does Aptinyx pay dividends?
                Aptinyx does not currently pay dividends.
                What is Aptinyx’s EPS estimate?
                Aptinyx’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Aptinyx have?
                Aptinyx has 67,720,000 shares outstanding.
                  What happened to Aptinyx’s price movement after its last earnings report?
                  Aptinyx reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.304. Following the earnings report the stock price went up 16.667%.
                    Which hedge fund is a major shareholder of Aptinyx?
                    Among the largest hedge funds holding Aptinyx’s share is New Leaf Venture Partners, L.L.C.. It holds Aptinyx’s shares valued at 7M.

                      ---

                      Aptinyx Stock Analysis

                      The Aptinyx stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Aptinyx Inc

                      Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Avrobio
                      Kezar Life Sciences
                      Mersana Therapeutics
                      Xeris Pharmaceuticals
                      Magenta Therapeutics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis